By Olde Del Mar Surgical
In recent years, GLP-1 receptor agonists like semaglutide and tirzepatide have gained prominence for their effectiveness in managing type 2 diabetes and aiding weight loss. However, the surge in demand has led to the emergence of unapproved and compounded versions of these drugs, raising significant safety concerns. The U.S. Food and Drug Administration (FDA) has issued warnings about the potential dangers associated with these unregulated alternatives.
Understanding Unapproved GLP-1 Drugs
Unapproved versions of GLP-1 receptor agonists are those that have not undergone the FDA’s rigorous evaluation for safety, efficacy, and quality. Compounded drugs, while sometimes necessary when FDA-approved options are unavailable, are custom-made medications that do not receive the same level of scrutiny. The FDA emphasizes that compounded drugs should only be considered when a patient’s specific medical needs cannot be met by approved medications.
Dosing Concerns with Compounded Semaglutide and Tirzepatide
The FDA has received multiple reports of adverse events, some requiring hospitalization, related to dosing errors with compounded injectable semaglutide products. These errors often stem from patients measuring and self-administering incorrect doses, and in some instances, healthcare professionals miscalculating dosages. Additionally, there have been cases where patients were prescribed compounded semaglutide or tirzepatide in doses exceeding those specified in the FDA-approved drug labels, leading to serious health complications.
Adverse Events Linked to Compounded Versions
As of February 28, 2025, the FDA has documented over 455 adverse event reports associated with compounded semaglutide and more than 320 related to compounded tirzepatide. While it’s challenging to determine if these events are directly caused by the compounded drugs, the lack of mandatory adverse event reporting for state-licensed pharmacies suggests that the actual number may be higher. Many of these adverse events mirror those observed with FDA-approved versions, underscoring the potential risks of using unapproved compounds.
Recommendations for Patients
To ensure safety and efficacy:
- Obtain Medications from Licensed Pharmacies: You are always better off using a prescription from a licensed pharmacy. If you use a compounded product, make sure that it is administered by a physician with experience and board certification and that it is sourced from a reliable pharmacy.
- Use trusted healthcare professionals: Engage in open discussions with your healthcare provider about your medications, ensuring you understand the proper usage and potential risks. Make sure your physician draws up the syringes that you are dispensed to avoid accidentally overdosing
- Be Cautious with Online Purchases: Utilize resources like the FDA’s BeSafeRx campaign to learn how to safely purchase prescription medicines online.
While the appeal of effective weight loss solutions is understandable, it’s crucial to prioritize safety by using only FDA-approved medications. Many patients cannot afford or have no insurance coverage for these medications. Using compounded versions of GLP-1 receptor agonists, while attractive, may pose significant risks due to potential dosing errors and unverified safety profiles. Always consult with healthcare professionals and rely on licensed pharmacies to ensure the medications you use are both safe and effective.
You May Also Like